BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 25968583)

  • 1. Rediscovery of the Anti-Pancreatic Antibodies and Evaluation of their Prognostic Value in a Prospective Clinical Cohort of Crohn's Patients: The Importance of Specific Target Antigens [GP2 and CUZD1].
    Papp M; Sipeki N; Tornai T; Altorjay I; Norman GL; Shums Z; Roggenbuck D; Fechner K; Stöcker W; Antal-Szalmas P; Veres G; Lakatos PL
    J Crohns Colitis; 2015 Aug; 9(8):659-68. PubMed ID: 25968583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic Autoantibodies Against CUZD1 and GP2 Are Associated with Distinct Clinical Phenotypes of Crohn's Disease.
    Michaels MA; Jendrek ST; Korf T; Nitzsche T; Teegen B; Komorowski L; Derer S; Schröder T; Baer F; Lehnert H; Büning J; Fellerman K; Sina C
    Inflamm Bowel Dis; 2015 Dec; 21(12):2864-72. PubMed ID: 26273818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies.
    Pavlidis P; Komorowski L; Teegen B; Liaskos C; Koutsoumpas AL; Smyk DS; Perricone C; Mytilinaiou MG; Stocker W; Forbes A; Bogdanos DP
    Clin Chem Lab Med; 2016 Feb; 54(2):249-56. PubMed ID: 26351932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autoantibodies against exocrine pancreas in Crohn's disease are directed against two antigens: the glycoproteins CUZD1 and GP2.
    Komorowski L; Teegen B; Probst C; Aulinger-Stöcker K; Sina C; Fellermann K; Stöcker W
    J Crohns Colitis; 2013 Nov; 7(10):780-90. PubMed ID: 23140841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease.
    Roggenbuck D; Hausdorf G; Martinez-Gamboa L; Reinhold D; Büttner T; Jungblut PR; Porstmann T; Laass MW; Henker J; Büning C; Feist E; Conrad K
    Gut; 2009 Dec; 58(12):1620-8. PubMed ID: 19549613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel immunoassays for detection of CUZD1 autoantibodies in serum of patients with inflammatory bowel diseases.
    Farkona S; Soosaipillai A; Filippou P; Liaskos C; Bogdanos DP; Diamandis EP; Blasutig IM
    Clin Chem Lab Med; 2017 Aug; 55(10):1574-1581. PubMed ID: 28343172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.
    Kovacs G; Sipeki N; Suga B; Tornai T; Fechner K; Norman GL; Shums Z; Antal-Szalmas P; Papp M
    PLoS One; 2018; 13(3):e0194166. PubMed ID: 29590158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Crohn's disease-specific anti-CUZD1 pancreatic antibodies are absent in ruminants with paratuberculosis.
    Liaskos C; Spyrou V; Athanasiou LV; Orfanidou T; Mavropoulos A; Rigopoulou EI; Amiridis GS; Shoenfeld Y; Billinis C; Bogdanos DP
    Clin Res Hepatol Gastroenterol; 2015 Jun; 39(3):384-90. PubMed ID: 25575461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic and clinical significance of Crohn's disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA.
    Pavlidis P; Shums Z; Koutsoumpas AL; Milo J; Papp M; Umemura T; Lakatos PL; Smyk DS; Bogdanos DP; Forbes A; Norman GL
    Clin Chim Acta; 2015 Feb; 441():176-81. PubMed ID: 25512163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.
    Bogdanos DP; Roggenbuck D; Reinhold D; Wex T; Pavlidis P; von Arnim U; Malfertheiner P; Forbes A; Conrad K; Laass MW
    BMC Gastroenterol; 2012 Aug; 12():102. PubMed ID: 22866900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease.
    Sipeki N; Davida L; Palyu E; Altorjay I; Harsfalvi J; Szalmas PA; Szabo Z; Veres G; Shums Z; Norman GL; Lakatos PL; Papp M
    World J Gastroenterol; 2015 Jun; 21(22):6952-64. PubMed ID: 26078573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease.
    Roggenbuck D; Reinhold D; Wex T; Goihl A; von Arnim U; Malfertheiner P; Büttner T; Porstmann T; Porstmann S; Liedvogel B; Bogdanos DP; Laass MW; Conrad K
    Clin Chim Acta; 2011 Apr; 412(9-10):718-24. PubMed ID: 21195704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibodies against glycoprotein 2 are novel markers of intestinal inflammation in patients with an ileal pouch.
    Werner L; Sturm A; Roggenbuck D; Yahav L; Zion T; Meirowithz E; Ofer A; Guzner-Gur H; Tulchinsky H; Dotan I
    J Crohns Colitis; 2013 Dec; 7(11):e522-32. PubMed ID: 23639628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serologic Anti-GP2 Antibodies Are Associated with Genetic Polymorphisms, Fibrostenosis, and Need for Surgical Resection in Crohn's Disease.
    Degenhardt F; Dirmeier A; Lopez R; Lang S; Kunst C; Roggenbuck D; Reinhold D; Szymczak S; Rogler G; Klebl F; Franke A; Rieder F
    Inflamm Bowel Dis; 2016 Nov; 22(11):2648-2657. PubMed ID: 27753692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of Crohn's disease-related anti-glycoprotein 2 antibodies in patients with celiac disease.
    Roggenbuck D; Vermeire S; Hoffman I; Reinhold D; Schierack P; Goihl A; von Arnim U; De Hertogh G; Polymeros D; Bogdanos DP; Bossuyt X
    Clin Chem Lab Med; 2015 Aug; 53(9):1349-57. PubMed ID: 25411995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoantibodies Against Glycoprotein 2 Isoforms in Pediatric Patients with Inflammatory Bowel Disease.
    Röber N; Noß L; Goihl A; Reinhold D; Jahn J; de Laffolie J; Johannes W; Flemming GM; Roggenbuck D; Conrad K; Laass MW
    Inflamm Bowel Dis; 2017 Sep; 23(9):1624-1636. PubMed ID: 28691939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of tolerance to gut immunity protein, glycoprotein 2 (GP2) is associated with progressive disease course in primary sclerosing cholangitis.
    Tornai T; Tornai D; Sipeki N; Tornai I; Alsulaimani R; Fechner K; Roggenbuck D; Norman GL; Veres G; Par G; Par A; Szalay F; Lakatos PL; Antal-Szalmas P; Papp M
    Sci Rep; 2018 Jan; 8(1):399. PubMed ID: 29321484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of tolerance to glycoprotein 2 isoforms 1 and 4 is associated with Crohn's disease of the pouch.
    Cummings D; Cruise M; Lopez R; Roggenbuck D; Jairath V; Wang Y; Shen B; Rieder F
    Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1251-1259. PubMed ID: 30411391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic Potential of Zymogen Granule Glycoprotein 2 Antibodies as Serologic Biomarkers in Chinese Patients With Crohn Disease.
    Zhang S; Wu Z; Luo J; Ding X; Hu C; Li P; Deng C; Zhang F; Qian J; Li Y
    Medicine (Baltimore); 2015 Oct; 94(42):e1654. PubMed ID: 26496271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-GP2 IgA autoantibodies are associated with poor survival and cholangiocarcinoma in primary sclerosing cholangitis.
    Jendrek ST; Gotthardt D; Nitzsche T; Widmann L; Korf T; Michaels MA; Weiss KH; Liaskou E; Vesterhus M; Karlsen TH; Mindorf S; Schemmer P; Bär F; Teegen B; Schröder T; Ehlers M; Hammers CM; Komorowski L; Lehnert H; Fellermann K; Derer S; Hov JR; Sina C
    Gut; 2017 Jan; 66(1):137-144. PubMed ID: 27406039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.